A laboratory comparison measured diazepam and three metabolites in aquatic products. Its results illustrate matrix-specific validation and should not be transferred directly to human blood testing.
Yang and colleagues developed extraction and cleanup for diazepam, nordazepam, oxazepam, and temazepam in aquatic-product matrices. They compared an Orbitrap high-resolution platform with tandem mass spectrometry using internal-standard quantification.
Both platforms showed strong calibration performance and agreement under the tested conditions. The paper reported detection and quantitation limits as low as 0.1 and 0.2 micrograms/kg, respectively, with analyte- and condition-dependent recovery and precision.
A high correlation between platforms means results varied together in the tested samples. It does not by itself establish absence of systematic bias, equal uncertainty at every concentration, or equivalent performance in an untested matrix.
Recoveries extended both below and above 100%, making the actual validation conditions relevant. The paper concerns chemical measurement in food-related matrices, rather than symptoms in humans or postmortem redistribution.
The study is useful when explaining why matrix, extraction, calibration, and identification criteria belong in a method assessment. A laboratory cannot simply borrow the paper’s reporting limits for blood or urine. Nor does detecting a benzodiazepine metabolite in an aquatic product establish the metabolic history of a human patient.
Original analysis of the supplied paper: Construction and Comparison of UPLC QE Orbitrap MS and UPLC MS MS Methods for the Detection of Diaze. Paper identifier: PMC12524225.